Sunflower Pharmaceutical (002737.SZ) plans to increase capital by 60 million yuan Linjiang Sunflower to improve its asset structure

Zhitongcaijing · 11/26 07:49

Zhitong Finance App News, Sunflower Pharmaceutical (002737.SZ) announced that the company plans to use its own capital of RMB 60 million to increase the capital of its subsidiary Sunflower Pharmaceutical Group (Jilin) Linjiang Co., Ltd. (“Linjiang Sunflower”). After the capital increase is completed, Linjiang Sunflower's registered capital will increase to 100 million yuan.

According to the announcement, Linjiang Sunflower was founded in 2002, and the company completed the acquisition in 2015. Its main products are five ginseng clam extract, stomach pain relief capsules, ginseng oral liquid, Xinniangkang capsules, Shiwu Yangxin oral liquid, etc., which are characteristic varieties of the company in the field of chronic supplements for the elderly. The company's current capital increase with its own capital will help improve the asset structure of Linjiang Sunflower, enhance Linjiang Sunflower's overall resilience to risks, and help effectively implement the company's strategy in the field of chronic supplement medication for the elderly.